IL2 and cancer: Jablons et al. (1990) demonstrated that in vivo administration of IL-2 in humans with advanced cancers suppresses FcγR expression (CD16) and chemotaxis in neutrophils whereas another study had opposite results and was performed in vitro to check the direct effect of IL-2 on the neutrophils functions (Girard et al., 1996).